Phio Pharmaceuticals Corp. (PHIO): Shareholders' Equity
$20.15M
As of 2025-12-31
$12.60M
As of 2026-06-30
+23.0%
3-year compound annual growth
+9.1%
5-year compound annual growth
+8.5%
10-year compound annual growth
| Period ended | Shareholders' Equity | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $20.15M | +326.6% | 2026-03-05, Balance as of period end |
| 2024-12-31 | $4.72M | -38.9% | 2026-03-05, Balance as of period end |
| 2023-12-31 | $7.73M | -28.7% | 2025-03-31, Balance as of period end |
| 2022-12-31 | $10.84M | -50.6% | 2024-04-01, Balance as of period end |
| 2021-12-31 | $21.93M | +68.5% | 2023-03-22, Balance as of period end |
| 2020-12-31 | $13.02M | +126.5% | 2022-03-22, Balance as of period end |
| 2019-12-31 | $5.75M | -57.7% | 2021-03-25, Balance as of period end |
| 2018-12-31 | $13.58M | +640.8% | 2020-03-26, Balance as of period end |
| 2017-12-31 | $1.83M | -83.1% | 2019-03-27, Balance as of period end |
| 2016-12-31 | $10.86M | +22.1% | 2018-03-26, Balance as of period end |
| 2015-12-31 | $8.89M | +223.9% | 2017-03-30, Balance as of period end |
| 2014-12-31 | $2.75M | -44.5% | 2016-03-30, Balance as of period end |
| 2013-12-31 | $4.94M | n/m | 2015-03-30, Balance as of period end |
| 2012-12-31 | -$5.84M | n/m | 2014-03-28, Balance as of period end |
| 2011-12-31 | -$587.0K | n/m | 2014-03-28, Balance as of period end |
| 2010-12-31 | $2.43M | +227.9% | 2014-03-28, Balance as of period end |
| 2009-12-31 | $741.0K | -91.7% | 2014-03-28, Balance as of period end |
| 2008-12-31 | $8.97M | -17.1% | 2014-03-28, Balance as of period end |
| 2007-12-31 | $10.82M | n/m | 2014-03-28, Balance as of period end |
| 2006-12-31 | $2.0K | n/m | 2014-03-28, Balance as of period end |
| 2005-12-31 | -$450.0K | n/m | 2013-03-29, Balance as of period end |
| 2004-12-31 | -$968.0K | n/m | 2013-03-29, Balance as of period end |
| 2003-12-31 | -$89.0K | n/a | 2013-03-29, Balance as of period end |
Shareholders' Equity at similar companies
| Company | Year ended | Shareholders' Equity | Change YoY |
|---|---|---|---|
| Phio Pharmaceuticals Corp. (PHIO) | 2025-12-31 | $20.15M | +326.6% |
| Emmaus Life Sciences, Inc. (EMMA) | 2025-12-31 | -$63.61M | n/m |
| BriaCell Therapeutics Corp. (BCTX) | 2025-07-31 | $17.33M | n/m |
| Annovis Bio, Inc. (ANVS) | 2025-12-31 | $16.85M | +81.0% |
| Abvc Biopharma, Inc. (ABVC) | 2025-12-31 | $11.11M | +806.2% |
| Moleculin Biotech, Inc. (MBRX) | 2025-12-31 | $15.01M | +33.9% |
| Jyong Biotech Ltd. (MENS) | 2025-12-31 | -$24.91M | n/m |
| Nexentis Technologies Inc. (NXTS) | 2025-12-31 | $16.01M | +237.1% |
| Quoin Pharmaceuticals Ltd. (QNRX) | 2025-12-31 | $13.12M | +42.5% |
Compare PHIO, EMMA, BCTX, ANVS side by side · Screen every company in Pharmaceutical Preparations ↗